Gamma Knife Dose Threshold of 57.6 Gy BED10 Flags True Tumor Growth After Treating Large Brain Metastases

When a tumor in the brain grows after being blasted with precisely targeted radiation, the most urgent question a doctor faces is deceptively simple: is the cancer really back, or is the swelling just the brain’s slow, angry response to the treatment itself? A new study from Japan offers one of the clearest answers yet to that dilemma, and it comes with a number that oncologists may soon memorize. Researchers at Komaki City Hospital and Nagoya University School of Medicine analyzed 143 patients with large brain metastases treated with Gamma Knife radiosurgery and found that delivering a biologically effective dose of at least 57.6 Gy significantly cut the risk of genuine tumor regrowth. Just as striking, they identified a timing signal that can distinguish true progression from a deceptive lookalike: when a growing tumor is accompanied by renewed swelling of the surrounding brain within the first year after treatment, the growth is almost certainly real and warrants early salvage therapy.

The study, published in the Journal of Neuro-Oncology, tackles a problem that has grown more pressing as whole-brain radiation therapy has fallen out of favor. Brain metastases, the spread of cancer to the brain from tumors elsewhere in the body, are estimated to occur in a substantial fraction of patients with advanced cancer, and as systemic therapies extend survival, more patients live long enough to face complications in the brain itself. Modern guidelines from ASTRO, ASCO, and the Society for Neuro-Oncology favor stereotactic radiosurgery, which concentrates high radiation doses on individual tumors while sparing healthy tissue. But large lesions, defined in this study as those with a volume of at least 4 cubic centimeters, pose a special challenge. A single massive dose of radiation risks injuring surrounding brain tissue, so clinicians must choose between single-session treatment, splitting the dose into staged sessions weeks apart, or delivering it in a handful of larger-than-conventional fractions known as hypofractionation. Which strategy works best, and at what dose, has remained genuinely uncertain.

The research team, led by Yuta Koketsu and corresponding author Toshinori Hasegawa, took advantage of a decade of experience at a single Gamma Knife center. Between 2016 and 2024, they treated patients with large brain metastases using all three approaches, individualizing both the treatment schedule and the radiation dose to each patient’s anatomy and clinical situation. For the analysis, they focused on one dominant lesion per patient and tracked it with serial imaging. Radiographic progression was defined conservatively as an increase of at least 20 percent in the longest tumor diameter from its smallest recorded size, the nadir. But the investigators went a crucial step further than most radiographic studies. They distinguished true progression, meaning enlargement that persisted or forced the team to intervene with additional treatment, from pseudoprogression, in which a lesion that initially appeared to grow later stabilized or shrank on its own without any salvage therapy. This distinction matters enormously, because treating pseudoprogression with more radiation or surgery exposes patients to harm for a problem that would have resolved by itself.

The headline result concerns dose. Using the concept of biologically effective dose, a radiobiological formula that converts different dose-and-fractionation schedules into a single number reflecting the expected biological effect on tumor cells, the team found a clear threshold. Lesions that received a BED10 of at least 57.6 Gy had a significantly lower risk of true progression, with a subdistribution hazard ratio of 0.46, meaning the hazard was cut by more than half, and the difference was statistically significant at p equals 0.02. In practical terms, the BED10 framework rewards clinicians for thinking beyond the raw dose number on a treatment plan. A modest dose delivered in a single session and a larger total dose spread over several sessions can be biologically equivalent to tumor cells, and the 57.6 Gy threshold gives clinicians a common currency for comparing schedules. Notably, the analysis found that true progression rates did not differ significantly by treatment modality, whether single-session, staged, or hypofractionated, or by tumor volume, suggesting that what matters is the total biological punch delivered rather than the specific way it is packaged.

The cumulative incidence figures tell the story of what patients face over time. At six months after Gamma Knife surgery, 17.4 percent of lesions had undergone true progression. By twelve months, that figure had climbed to 31.5 percent, and by twenty-four months it had essentially plateaued at 33.1 percent. That plateau is clinically meaningful: it suggests that if a large treated metastasis is going to truly regrow, it almost always does so within the first year, and a patient who reaches the two-year mark with local control is unlikely to lose it. The median overall survival of the entire cohort was 15.3 months, which means that for a large share of these patients, the question of local tumor control is not academic; it unfolds within their actual lifespan and directly affects their quality of life and neurological function.

Of the 143 lesions followed, 47 eventually showed radiographic progression, but the breakdown reveals how treacherous imaging interpretation can be. Forty-two turned out to be true progression, four were pseudoprogression, and one was attributed to intratumoral hemorrhage. In other words, roughly one in ten radiographic failures was not a failure at all. The pseudoprogression phenomenon reflects radiation necrosis, a delayed injury to brain tissue in and around the treated lesion that can cause the enhancing area on MRI to enlarge, mimic tumor growth, produce mass effect and edema, and even bring back a patient’s original neurological symptoms. Biopsy series from other centers have repeatedly shown that enlarging lesions after radiosurgery frequently contain necrosis rather than viable tumor. The Komaki team illustrated the point vividly in a supplementary case: a man in his seventies with a 66 cubic centimeter occipital metastasis causing hemianopsia and Gerstmann syndrome received two-stage Gamma Knife treatment with 12 Gy per stage. His symptoms resolved and the tumor shrank dramatically, but a year later the lesion enlarged again with worsening edema and recurrent vision loss, apparently demanding salvage therapy. Instead, it stabilized on its own at eighteen months and the edema improved by twenty-two months, consistent with radiation necrosis running its natural course.

How, then, can clinicians tell the impostor from the real thing? The study’s most actionable finding is a timing signature. Recurrent peritumoral edema, the reappearance or worsening of fluid accumulation in brain tissue around the lesion, developed far earlier in true progression than in pseudoprogression, with a median of 173.5 days versus 564 days, a difference that was highly significant at p equals 0.001. When tumor enlargement and renewed edema arrive together within roughly the first year after treatment, the pattern strongly indicates genuine tumor regrowth, and the authors conclude that such a finding should prompt consideration of early salvage intervention rather than a prolonged wait-and-see approach. Conversely, enlargement with edema emerging well beyond the one-year mark is more consistent with late radiation necrosis, where observation may spare the patient unnecessary surgery or reirradiation. This simple temporal rule requires no advanced imaging, no perfusion sequences, no spectroscopy, and no biopsy, only careful attention to the calendar alongside the MRI.

The study also speaks to what happens when a lesion does fail and clinicians reach for a second round of Gamma Knife treatment. Among patients who underwent repeat radiosurgery, a lower marginal dose at the second session was associated with subsequent true progression, with a hazard ratio of 0.82 per dose increment, significant at p equals 0.02. The interpretation is sobering: underdosing at salvage treatment appears to invite another failure, yet pushing the dose higher raises the specter of radiation necrosis, particularly since the surrounding tissue has already been irradiated. Repeat stereotactic radiosurgery for recurrent brain metastases is well established in the literature, with systematic reviews and meta-analyses documenting both its efficacy and its necrosis risk, and the new data add a quantitative argument for dosing salvage sessions deliberately rather than timidly. The team notes that their institution has also explored combined approaches, including reirradiation followed by resection, for select recurrent lesions.

Why does dose matter so much biologically? The answer lies in classic radiation biology. Tumor cells vary in their oxygenation, and cells at intermediate oxygen levels can substantially influence the response of a tumor to fractionated radiotherapy, a relationship explored in foundational work by Wouters and Brown. Hypoxic cells require more radiation to kill, and fractionation schedules that allow tumor reoxygenation between sessions can partially compensate, which is precisely why the BED10 framework, which encodes the effect of fractionation, is a better predictor of control than the physical dose alone. Large metastases are also more likely than small ones to contain poorly oxygenated cores and to press against eloquent brain structures that force dose reductions, creating a tension between tumor control and toxicity that the 57.6 Gy threshold helps clinicians navigate quantitatively.

The study’s limitations are those inherent to its design: it was retrospective, conducted at a single institution, and treatment decisions were individualized rather than randomized, so selection biases cannot be fully excluded. Datasets are available from the corresponding author on reasonable request, and the work received no specific external funding. Still, the practical takeaways are hard to ignore. For patients with large brain metastases, the total biologically effective dose delivered to the tumor edge should be planned to reach at least 57.6 Gy BED10, using whatever fractionation scheme best protects the surrounding brain. And in follow-up, the pairing of tumor enlargement with recurrent peritumoral edema within a year of Gamma Knife surgery should be read not as an ambiguous radiological curiosity but as a call to act, because in this disease, waiting for certainty can cost patients the window in which salvage treatment works best.

Subject of Research: Dose selection and progression assessment after Gamma Knife radiosurgery for large brain metastases

Article Title: Dose selection and clinical decision-making after Gamma Knife surgery for large brain metastases: implications for early identification of true progression

Article References: Koketsu, Y., Hasegawa, T., Kato, T., Naito, T., Mizuno, A., Ando, Y., Kosaka, N., & Saito, R. (2026). Dose selection and clinical decision-making after Gamma Knife surgery for large brain metastases: implications for early identification of true progression. Journal of Neuro-Oncology, 180(1), Article 3. https://doi.org/10.1007/s11060-026-05792-0

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05792-0

Keywords: Gamma Knife surgery, stereotactic radiosurgery, brain metastases, biologically effective dose, pseudoprogression, radiation necrosis, peritumoral edema, salvage therapy, hypofractionation, tumor progression, radiation oncology, neuro-oncology